Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Three-period Cross-over Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts (Maleate and Acetate) Delivered Via the Concept1 Inhalation Device in Patients With Asthma
Conditions
Interventions
Indacaterol maleate
Indacaterol acetate
+1 more
Locations
6
United States
Novartis Investigative Site
North Dartmouth, Massachusetts, United States
Novartis Investigative Site
St Louis, Missouri, United States
Novartis Investigative Site
Skillman, New Jersey, United States
Novartis Investigative Site
Raleigh, North Carolina, United States
Novartis Investigative Site
Medford, Oregon, United States
Novartis Investigative Site
El Paso, Texas, United States
Start Date
September 5, 2017
Primary Completion Date
January 17, 2018
Completion Date
January 18, 2018
Last Updated
January 5, 2021
NCT07431021
NCT07383896
NCT07282886
NCT06003569
NCT05562466
NCT02327897
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions